Outcomes of pregnancies among isotretinoin users (during treatment or up to 42 weeks after the end of treatment), based on the high-specificity definition of pregnancy
| Outcome | Province; no. (%) of pregnancies | ||||
|---|---|---|---|---|---|
| BC | Saskatchewan | Manitoba* | Ontario† | Overall | |
| All pregnancies | 912 | 96 | 150 | 315 | 1 473 |
| Spontaneous pregnancy losses‡ | 199 (21.8) | 34 (35.4) | 34 (22.7) | 23 (7.3) | 290 (19.7) |
| Induced abortion (including TOPFA) | 689 (75.5) | 44 (45.8) | 103 (68.7) | 205 (65.1) | 1 041 (70.7) |
| Live birth, with or without congenital malformation | 24 (2.6) | 18 (18.8) | 11 (7.3) | 65 (20.6) | 118 (8.0) |
| Live birth with congenital malformation | Suppressed§ | Suppressed§ | Suppressed§ | Suppressed§ | 11¶ |
Note: BC = British Columbia, TOPFA = termination of pregnancy for fetal abnormality.
↵* For 2 cases in Manitoba, the outcome could not be categorized because of small-cell suppression rules.
↵† For 22 cases in Ontario, no pregnancy outcome was documented.
↵‡ Includes spontaneous abortions and a very small number of stillbirths.
↵§ Data suppressed to protect patient confidentiality.
↵¶ The cases with outcome of congenital malformation (n = 11) represented 0.7% of all pregnancies and 9.3% of live births.